Lynparza (olaparib), in combination with bevacizumab, has been recommended for approval in the European Union (EU) as a first-line maintenance therapy for women with advanced ovarian cancer positive for homologous recombination deficiency (HRD) and who responded to platinum-based chemotherapy. The positive opinion released by the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, also includes patients who have advanced fallopian tube or primary peritoneal cancer. CHMP’s recommendations are generally accepted by the European Commission, which…
You must be logged in to read/download the full post.
The post Lynparza Combo Recommended by EU Committee as First-line Maintenance for Advanced Ovarian Cancer appeared first on BioNewsFeeds.